Original Research

Efficacy of Coronary Calcium Score in Predicting Coronary Artery Morphology in Patients With Obstructive Coronary Artery Disease

Xingwei He, MDa,b,†, Soe Maung, MBChB a,f, Anantharaman Ramasamy, MBChB, PhD b,c, Mohamed O. Mohamed, PhD c,d, Retesh Bajaj, MBChB a,c, Nathan Angelo Lecaros Yap, MBChB g, Medeni Karaduman, MD h, Yaojun Zhang, MD f, Pieter Kitslaar, MSc g,h, Alexander Broersen, PhD h, Johan H.C. Reiber, PhD g,h, Jouke Dijkstra, PhD h, Patrick W. Serruys, MD, PhD i,j, James C. Moon, MD a,k, Andreas Baumbach, MD, PhD b,c, Ryo Torii, MSc, PhD l, Francesca Pugliese, MD, PhD b,c,†, Christos V. Bourantas, MD, PhD b,c,†a

a Department of Cardiology, Barts Health NHS Trust, London, United Kingdom; b Division of Cardiology, Department of Internal Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China; c Centre for Cardiovascular Medicine and Devices, William Harvey Research Institute, Queen Mary University of London, London, United Kingdom; d Institute of Health Informatics, University College London, London, United Kingdom; e Department of Cardiology, Faculty of Medicine, Yuzuncu Yil University Van, Van, Turkey; f Department of Cardiology, Xuzhou Third People’s Hospital, Xuzhou, China; g Division of Image Processing, Department of Radiology, Leiden University Medical Center, Leiden, the Netherlands; h Medis Medical Imaging Systems, Leiden, the Netherlands; i Faculty of Medicine, National Heart & Lung Institute, Imperial College London, London, United Kingdom; j Department of Cardiology, University of Galway, Galway, Ireland; k Institute of Cardiovascular Sciences, University College London, London, United Kingdom; l Department of Mechanical Engineering, University College London, London, United Kingdom

ABSTRACT

Background: Coronary artery calcium score (CACS) is an established marker of coronary artery disease (CAD) and has been extensively used to stratify risk in asymptomatic individuals. However, the value of CACS in predicting plaque morphology in patients with advanced CAD is less established. The present analysis aims to assess the association between CACS and plaque characteristics detected by near-infrared spectroscopy-intravascular ultrasound (NIRS-IVUS) imaging in patients with obstructive CAD.

Methods: Seventy patients with obstructive CAD underwent coronary computed tomography angiography (CTA) and 3-vessel NIRS-IVUS imaging were included in the present analysis. The CTA data were used to measure the CACS in the entire coronary tree and the segments assessed by NIRS-IVUS, and these estimations were associated with the NIRS-IVUS measurements at a patient and segment level.

Results: In total, 65 patients (188 segments) completed the study protocol and were included in the analysis. A weak correlation was noted between the CACS, percent atheroma volume (r = 0.271, P = .002), and the calcific burden measured by NIRS-IVUS (r = 0.648, P < .001) at patient-level analysis. Conversely, there was no association between the CACS and the lipid content, or the incidence of high-risk plaques detected by NIRS. Linear regression analysis at the segment level demonstrated an association between the CACS and the total atheroma volume (coefficient, 0.087; 95% CI, 0.024-0.149; P = .002), but there was no association between the lipid content or the incidence of high-risk lesions.

Conclusions: In patients with obstructive CAD, the CACS is not associated with the lipid content or plaque phenotypes. These findings indicate that the CACS may have a limited value for screening or stratifying cardiovascular risk in symptomatic patients with a high probability of CAD.

Abbreviations: CaBI, calcific burden index; CACS, coronary artery calcium score; CAD, coronary artery disease; CTA, coronary computed tomography angiography; EEM, external elastic membrane; LCBI, lipid core burden index; NIRS-IVUS, near-infrared spectroscopy-intravascular ultrasound; PAV, percent atheroma volume; PCI, percutaneous coronary intervention; TAV, total atheroma volume.

Keywords: coronary artery disease; coronary calcium score; coronary computed tomography angiography; near-infrared spectroscopy-intravascular ultrasound; risk stratification; vulnerable plaque.

† Corresponding author: c.bourantas@gmail.com (C.V. Bourantas).
† Co-first authors.

https://doi.org/10.1016/j.jscai.2024.101308
Received 2 January 2024; Received in revised form 11 January 2024; Accepted 12 January 2024
Available online 26 March 2024
2772-9303/© 2024 The Author(s). Published by Elsevier Inc. on behalf of the Society for Cardiovascular Angiography and Interventions Foundation. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction

Coronary artery calcium score (CACS) assessment provides useful prognostic information and enables the identification of patients at risk of suffering cardiovascular events. Cumulative data have shown that an increased CACS is a marker of coronary atherosclerosis and is associated with a high event rate in asymptomatic patients with no previous cardiac history. Therefore, today CACS has IIB recommendation in the European Society of Cardiology guidelines for primary prevention for risk stratification and modifying treatment. However, in patients with advanced disease, the value of the CACS is less well established. A meta-analysis of the MESA study has demonstrated no difference in the incidence of hard clinical end points (death resuscitated cardiac arrest or myocardial infarction) in patients with high (400-999) and very high (>1000) CACS indicating that this tool may have a limited value in identifying vulnerable patients among those with advanced coronary artery disease (CAD). These findings were not supported, however, by most recent reports including an analysis of the MESA study, where the patients had a longer follow-up, showing that a very high CACS provides useful prognostic information and is associated with worse prognosis compared to a high CACS.

In an attempt to shed light on the value of CACS in assessing coronary artery phenotypes and predicting outcomes, a post hoc analysis of the SCOT-Heart study examined the association between CACS and plaque characteristics in patients with chest pain and demonstrated that high-risk plaque characteristics detected by coronary computed tomography angiography (CTA) increase between patients with 0, minimal (1-9) and low (10-99) CACS but did not increase further in patients with moderate (100-399), high (400-999) and very high (>1000) CACS. Intravascular imaging studies assessing the performance of CACS in evaluating plaque morphology have provided contradictory results with some studies showing a strong association and others no correlation between CACS and the lipid component. The present study aims to provide additional insights into the value of the CACS in predicting plaque morphology and examines in a large number of patients with advanced CAD, the association between CACS and plaque characteristics detected by near-infrared spectroscopy-intravascular ultrasound (NIRS-IVUS).

Methods

Study population

This is a post hoc analysis of a recently conducted study that aimed to examine the safety and efficacy of CTA in assessing coronary artery morphology and physiology using NIRS-IVUS as a reference standard. The study included 70 patients with chronic coronary syndrome who had an invasive coronary angiogram demonstrating obstructive CAD which required either further assessment or treatment with percutaneous coronary intervention (PCI). All patients underwent CTA before being listed for repeat coronary angiography, PCI (if needed), and 3-vessel NIRS-IVUS imaging. The study was conducted in line with the Declaration of Helsinki and approved by the local ethics committee (REC reference: 17/SC/0566). All participants provided written informed consent before study enrolment.

CTA data acquisition

Coronary computed tomography angiography was performed using a third-generation dual-source computed tomography (CT) scanner (SOMATOM Force, Siemens Healthineers). Before CTA, participants received sublingual nitroglycerin (400 μg), and intravenous metoprolol (maximum 40 mg), when their heart rate was >70 beats per minute, provided there was no contraindication. Scan parameters included prospective ECG-triggered sequential scan mode, gantry rotation time of 250 ms, 128 x 2 x 0.5 mm, collimation with z-flying focal spot for both detectors, and a minimum tube voltage of 100 kV defined by the CareKv algorithm, whereas the tube current was determined by the scanner. In this study, noncontrast CT imaging was not performed so as to minimize additional radiation.

NIRS-IVUS data acquisition

NIRS-IVUS imaging was performed in all the recruited patients before PCI in their 3 major epicardial vessels and large side branches (diameter ≥2 mm) using a 2.4F Makoto NIRS-IVUS 35-65 MHz Imaging System (Infraredx). The probe was advanced to the distal end of the vessel and then was withdrawn using an automated pull-back device at a speed of 0.5 mm/s. If an obstructive lesion prohibited the advancement of the NIRS-IVUS probe, then this was predicated before NIRS-IVUS imaging with a 2-mm balloon.

NIRS-IVUS and CTA data analysis and coregistration

Coronary artery calcium score computation was performed using commercially available CT plaque analysis software (QAngioCT Research Edition 3.1, Medis Medical Imaging Systems). The coronary tree was extracted and the most proximal and distal side branches that were visible on both CTA and NIRS-IVUS were identified and used to define a segment of interest—ie, the coronary segment that was assessed by both modalities. Stented segments, segments with poor image quality, and those with significant artifacts were excluded from the analysis.

The NIRS-IVUS data corresponding to the segment of interest were analyzed, by an expert analyst with an established reproducibility, blinded to the CTA images. First the NIRS-IVUS end-diastolic frames were automatically extracted using an in-house deep learning methodology and then in these frames the lumen and external elastic membrane (EEM) borders were detected. In addition, the circumferential distribution of the calcific tissue was manually annotated with an arc and these annotations together with the lipid core distribution, derived from NIRS, were used to generate a 2-dimensional (2D) color-coded map displaying the lipid core in yellow, and calcium in semitransparent white with the X-axis indicating the longitudinal and the Y-axis the circumferential location of the different plaque components.

Coronary artery calcium score computation was performed using a previously described method designed to estimate the CAC in contract CT that has been incorporated in an in-house customized research version of CalcScore software (V1.1.1 by Medis Specials bv, Figure 1). Axial planes that were 3 mm apart were defined and in these, the coronary calcium was automatically detected as the areas in the coronary arteries that had a minimum Hounsfield Unit (HU) threshold above that of the lumen HU values, so as to differentiate calcific tissue from the lumen volume, and an area >1 mm², which is the reference value in conventional calcium scoring analysis. In this study we did not use a prespecified HU cutoff to define the presence of calcium but a patient-specific cutoff as there is a discrepancy in the literature about the optimal HU cutoff for detecting calcification in CTA. To ensure accurate and reproducible detection of coronary calcification, the analyst was able to inspect during this process the multiplanar curve reconstructed CTA images, identify in these the presence of coronary calcification, and ensure that the selected HU cutoff in the CalcScore software allowed detection of coronary calcification in axial planes. The analysis was performed by an operator (C.V.B.) with 6 years of experience in CTA analysis for each segment of interest assessed by NIRS-IVUS and for the entire coronary artery tree. Stented segments were excluded from the CACS computation.
Figure 1.
Snapshots of the CalcScore software used for the coronary artery calcium score (CACS) computation. Panel (A) illustrates an axial CT plane where the analyst can identify the presence of coronary calcification and apply the optimal HU cutoff that allows automated detection of calcific tissue. The estimations of the algorithm are displayed in panel (B), and depending on the vessel, are shown in different colors (red for the RCA, green for the LAD, and blue for the LCx). After the automated detection of the calcific tissue, the CACS is computed for each coronary artery and for the entire coronary tree (C). LAD, left anterior descending artery; LCx, left circumflex coronary artery; RCA, right coronary artery.
The interobserver variability of the analyst was tested in a set of 25 patients against the estimations of a second operator; in this set, the analysis was repeated twice to also test the expert’s intraobserver variability. Analysts’ variability was tested using the intraclass correlation coefficient (ICC).

Association of CACS and plaque characteristics

The association between CACS and plaque characteristics was examined at segment- and patient-levels.

**Segment-level analysis.** The lumen and EEM borders detected in NIRS-IVUS images were used to compute the lumen, EEM, total atheroma volume (TAV, defined as EEM – lumen volume), and percent atheroma volume (PAV, defined as $100 \times TAV$ divided by the EEM volume). In addition, the maps of plaque distribution were used to compute the lipid core burden index (LCBI, defined as the fraction of the yellow pixels multiplied by 1000), the calcific burden index (CaBI, defined as the number of pixels indicating the presence of calcium, multiplied by 1000 and divided by the total number of pixels) and the $\text{maxLCBI}_{4\text{mm}}$ indicating the maximum LCBI in a 4-mm segment (Figure 2).
Moreover, in each segment of interest, we detected the presence of lesions defined as 3 consecutive end-diastolic NIRS-IVUS frames with a plaque burden (defined as EEM–lumen area) >100 divided by the EEM area) >40%. If between lesions there was a disease-free segment with a length ≥5 mm, then these lesions were considered tandem lesions otherwise they were treated as a single lesion. Previous studies have shown that lesions with a minimum lumen area ≤4 mm² maximum plaque burden >70%, and maxLCBI4mm>400²⁴,²⁵,²⁶ are at risk of progressing and causing events. In the present analysis, the lesions that had all these 3 plaque characteristics were considered as high-risk lesions.

For each segment of interest, we examined the association between CACS and TAV, PAV, LCBI, CaBI, maxLCBI4mm, and the number of lesions detected. In addition, we compared the CACS in segments with high-risk lesions and in those without.

**Patient-level analysis.** The lumen and EEM volume measured in the segments of interest were used to estimate the total lumen and EEM volume and extract the TAV and PAV for each patient. Moreover, we computed the LCBI, CaBI, and maxLCBI4mm, and examined the association between the CACS estimated in the entire coronary tree of each patient with the above metrics. Finally, we reported the number of lesions detected by NIRS-IVUS and the presence of high-risk lesions and compared the CACS in patients with high-risk lesions with those without.

**Statistical analysis**

The Kolmogorov-Smirnov and Shapiro-Wilk tests were used to test the distribution of the numerical variables; for the normally distributed variables results are presented as mean and SD whereas for non-normally distributed variables as median and IQR; finally, categorical variables are shown as absolute values and percentages. The CACS was log-transformed, whereas the TAV, LCBI, CaBI, and maxLCBI4mm were transformed to their square root. A P value of <.05 was considered statistically significant. Analysis was performed using the SPSS Statistic 26 (IBM) and Stata/MP 16 (StataCorp LLC).

**Results**

**Studied patients**

Of the 70 patients recruited in the study, 65 completed the studied protocol; all these patients had successful CACS assessment and were included in the analysis (Figure 3). The mean age of the recruited patients was 61.42 ± 8.22 years; most of the patients suffered from hypertension and hypercholesterolemia and had a positive family history of ischemic heart disease. The baseline demographics of the included patients are shown in Table 1.²

NIRS-IVUS imaging was successfully performed in 197 coronary arteries 11.4 ± 6.9 days after CTA; matching of the NIRS-IVUS and CTA images was possible in 188 segments, and these were included in the final analysis.

**Association between CACS and plaque characteristics at the patient-level**

The CACS computed in the studied patients (median, 52; IQR, 11–159) was used to split the patients into terciles (first group CACS < 23, second group CACS between 23 and 108, and third group CACS > 108). Patients with high CACS had a higher body mass index and incidence of hypertension but otherwise, there were no significant differences in the baseline demographics between groups (Table 1).

The total length of the segments studied by NIRS-IVUS imaging was 171.5 ± 69.4 mm per patient and was similar in the 3 groups. The length of the left circumflex-obtuse marginals studied by NIRS-IVUS was larger.
in the intermediate CACS group but otherwise, there was no difference between groups in the length of vessels studied by NIRS-IVUS. The CACS analysis and the NIRS-IVUS analysis results are shown in Table 2. The lumen, EEM volume, TAV, and PAV as well as the LCBI and maxLCBI were similar in the 3 groups, whereas the CaBI increased from the first to the third group. The median number of lesions detected in the segments studied by NIRS-IVUS was 4 (IQR: 3-6) and was no different in the 3 CACS categories. There was also no difference in the incidence of high-risk lesions in patients with low, intermediate, and high CACS ($P = .628$).

A weak correlation was noted between CACS and the PAV ($r = 0.271; P = .002$), whereas the correlation was moderate between the CACS and the CaBI ($r = 0.648; P < .001$). Conversely, there was no correlation between CACS and LCBI and maxLCBI. Binary logistic regression analysis did not demonstrate an association between CACS and the presence of high-risk lesions ($P = .306$).

### Association of plaque composition and CAC at the segment level

The median length of the segments of interest was 54.79 (38.92-78.19). The mean CACS in these segments was 29.6 ± 68.0 and the median CACS was 0 (0-120.0). The TAV estimated by NIRS-IVUS was 296 (150.0-469.5) mm$^3$ and the PAV was 41.21 ± 9.89%. The LCBI was measured to be 38.27 (5.73-97.02), the CaBI 55.09 (16.59-119.97), and the maxLCBI was 261.15 (73.50-418.50). In total, 300 lesions were identified; the median number of lesions per segment was 1 (1-2) of which 25 (8.3%) were classified as high-risk lesions (only 1 segment had 2 high-risk lesions).

Linear regression analysis showed no association between segment-level log-transformed CACS and PAV, and root square LCBI and maxLCBI. Conversely, there was a significant association between the log-transformed CACS and the root-squared TAV and CaBI (Table 3, Figure 4). The number of lesions identified in the segments of interest, and the incidence of high-risk plaques, did not correlate with the CACS.

### Reproducibility of CACS computation

An excellent agreement was noted between the estimations of the 2 analysts for the CACS measured in the entire coronary tree (ICC, 0.986; $P < .001$), and individually in each segment of interest assessed by NIRS-IVUS (ICC, 0.996; $P < .001$). Moreover, the reproducibility of the expert analyst who performed the analysis twice was also high and close

### Table 1. Baseline demographics of the studied patients in different CAC score terciles

<table>
<thead>
<tr>
<th>Age, y</th>
<th>Low CAC score tercile (n = 22)</th>
<th>Intermediate CAC score tercile (n = 22)</th>
<th>High CAC score tercile (n = 21)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Male sex</td>
<td>61.42 ± 8.22</td>
<td>59.29 ± 9.57</td>
<td>60.95 ± 7.59</td>
</tr>
<tr>
<td>Smoking history</td>
<td>50 (76.9%)</td>
<td>14 (63.6%)</td>
<td>18 (81.8%)</td>
</tr>
<tr>
<td>Comorbidities</td>
<td>31 (47.7%)</td>
<td>11 (50%)</td>
<td>11 (50%)</td>
</tr>
<tr>
<td>LV dysfunction</td>
<td>40 (61.5%)</td>
<td>16 (72.7%)</td>
<td>14 (63.6%)</td>
</tr>
<tr>
<td>Hypertension</td>
<td>35 (53.8%)</td>
<td>11 (50%)</td>
<td>8 (36.4%)</td>
</tr>
<tr>
<td>Hypercholesterolemia</td>
<td>46 (70.8%)</td>
<td>17 (77.3%)</td>
<td>14 (63.6%)</td>
</tr>
<tr>
<td>Renal failure</td>
<td>4 (6.1%)</td>
<td>2 (9.1%)</td>
<td>2 (9.1%)</td>
</tr>
<tr>
<td>Previous PCI</td>
<td>14 (21.5%)</td>
<td>3 (13.6%)</td>
<td>4 (18.2%)</td>
</tr>
<tr>
<td>Previous CVA</td>
<td>6 (9.2%)</td>
<td>2 (9.1%)</td>
<td>2 (9.1%)</td>
</tr>
<tr>
<td>LAD—diagonals, mm</td>
<td>64.82 ± 32.10</td>
<td>62.78 ± 30.41</td>
<td>65.38 ± 39.45</td>
</tr>
<tr>
<td>LCx—obtuse marginals, mm</td>
<td>50.60 ± 28.16</td>
<td>62.20 ± 29.70</td>
<td>47.72 ± 22.05</td>
</tr>
<tr>
<td>RCA, mm</td>
<td>54.00 [0.96-43]</td>
<td>53.16 [0-81.17]</td>
<td>71.86 [0-105.35]</td>
</tr>
</tbody>
</table>

Values are mean ± SD, n (%), or median [IQR].

CAD, coronary artery disease; CVA, cerebrovascular accident; LAD, left anterior descending artery; LCx, left circumflex coronary artery; LV, left ventricle; PCI, percutaneous coronary intervention; RCA, right coronary artery.

### Table 2. CAC score and NIRS-IVUS analysis results in different CAC score terciles

<table>
<thead>
<tr>
<th>CAC score</th>
<th>Studied patients (N = 65)</th>
<th>Low CAC score tercile (n = 22)</th>
<th>Intermediate CAC score tercile (n = 22)</th>
<th>High CAC score tercile (n = 21)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total CAC score</td>
<td>1404.3 ± 763.9</td>
<td>1298.7 ± 565.3</td>
<td>1565.5 ± 955.1</td>
<td>1346.2 ± 727.6</td>
</tr>
<tr>
<td>Lumen volume, mm$^3$</td>
<td>2040.5 [1461.9-3130.4]</td>
<td>2093.8 [1452.3-2833.9]</td>
<td>2389.5 [1480-3419.1]</td>
<td>2096.2 [1461-3819.1]</td>
</tr>
<tr>
<td>TAV, mm$^3$</td>
<td>939.9 [591.6-1257.2]</td>
<td>794.0 [526.1-1145.6]</td>
<td>1010.1 [608.0-1447.6]</td>
<td>948.3 [591.6-1463.7]</td>
</tr>
<tr>
<td>LCBI</td>
<td>46.8 [20.6-88.8]</td>
<td>43.9 [23.4-65.3]</td>
<td>50.4 [17.3-88.8]</td>
<td>54.6 [32.4-106.8]</td>
</tr>
<tr>
<td>CaBI</td>
<td>73.9 [37.5-120.1]</td>
<td>41.7 [21.7-64.0]</td>
<td>73.0 [38.5-114.7]</td>
<td>128.8 [109.6-205.8]</td>
</tr>
<tr>
<td>maxLCBI</td>
<td>455.6 ± 227.4</td>
<td>420.2 ± 181.3</td>
<td>444.6 ± 221.6</td>
<td>504.2 ± 274.6</td>
</tr>
<tr>
<td>Presence of high-risk lesions</td>
<td>24 (36.9%)</td>
<td>9 (37.5%)</td>
<td>9 (37.5%)</td>
<td>6 (25.0%)</td>
</tr>
</tbody>
</table>

Values are median [IQR], mean ± SD, or n (%).

CAC, calcific burden index; CAC, coronary artery calcium; EEM, external elastic membrane; LCBI, lipid core burden index; PAV, percent atheroma volume; TAV, total atheroma volume.
to 1 (ICC, 0.996; P < .001 for the CACS measured in the entire coronary artery tree, and ICC, 0.992; P < .001 for the CACS measured in the segments of interest).

**Discussion**

In this study, we examined for the first time in patients with established CAD the association between plaque characteristics assessed by NIRS-IVUS and CACS. We found that the CACS was weakly associated with the PAV and CaBi at the patient-level analysis and with the TAV and CaBi at the segment-level analysis. Conversely, in this cohort of patients, there was no association between the CACS and the lipid component assessed by NIRS or the incidence of high-risk lesions (Central Illustration).

Several studies in the past have demonstrated that the CACS provides useful prognostic information in asymptomatic individuals whereas in symptomatic patients the prognostic value of the CACS is less well established.1-4,11,28 In the study by Mittal et al,28 0 CACS was associated with excellent clinical outcomes whereas in the study by Osborne-Grinters et al,11 10% of the patients who had an event at 4.8 years follow-up had 0 CACS at baseline. In the latter study, 13 of the patients with 0 CACS had CTA high-risk lesions with a large low attenuated vulnerable plaques (>4%) that is a predictor of adverse events.29

In this report, there was an association between CACS and plaque phenotypes with the patients having an increased CACS exhibiting more often low attenuated vulnerable plaques on CTA. Despite this association, however, plaque characteristics on CTA provided incremental prognostic information to CACS allowing better prediction of adverse events. These findings contradict a previous report that used NIRS-IVUS to assess plaque types and showed no association between plaque morphology and CACS and the results of Takamura et al.30 who failed to demonstrate a superiority of CACS over CACS in predicting outcomes.12 A possible explanation of these discrepancies is the fact that these 2 analyses included asymptomatic patients who are less likely to have advanced plaque characteristics and also a small number of patients who may have not provided enough power to draw safe conclusions.

The present study overcomes the above limitations and for the first time it examined in a large number of symptomatic patients, with established CAD, the association between plaque morphology derived by hybrid NIRS-IVUS and CACS. Similar to Madder et al.12 we found a significant association between CACS, atheroma burden, and CaBi at the patient- and segment-level analysis. The association between the CACS and CaBi estimated by NIRS-IVUS was only moderate; this should be attributed to the fact that the CACS depends not only on the calcific area but also on calcium density and is traditionally estimated in CT sections obtained at a 3 mm interval, whereas, the CaBi reflects the longitudinal and circumferential extend of calcium in NIRS-IVUS and in our study was computed at every end-diastolic frame (average frame interval < 0.5 mm). There is evidence that the difference in the longitudinal resolution between NIRS-IVUS and CACS affects their agreement for the calcific burden; in the study by Qian et al,31 the CACS quantified in slices with a thickness of 0.5 mm had a better agreement with the calcific burden derived by IVUS than the conventional CACS measured in slices with a thickness of 3 mm. The large slice thickness may also have affected the association between CACS and lipid and plaque burden derived by NIRS-IVUS, especially in segments with short (< 3 mm) lesions.32 The weak correlation between atheroma burden and CACS noted in our analysis compared to the study Madder et al.12 should be also attributed to the different inclusion criteria of the 2 studies; our population included patients with 0 CACS that had advanced CAD, whereas the study by Madder et al.12 recruited patients with CACS of ≥ 300 who had less advanced disease, as indicated by the incidence of high-risk lesions in this population. Despite these differences, our findings were similar when we examined the association between the lipid component and CACS. In contrast to the study by Choi et al.11 that found a significant correlation between necrotic core computed by virtual histology-IVUS and CACS, in our analysis and in the analysis of Madder et al.12 the lipid component detected by NIRS was not related to the CACS, which indicated that this modality may have limited predictive value in patients with advanced CAD. More importantly, CACS was not associated with the incidence of high-risk plaques identified by NIRS-IVUS imaging, as in our study 8 out of the 25 high-risk lesions were found in segments with 0 CACS; whereas, 1 in 5 patients with obstructive CAD had 0 CACS. The small number of

### Table 3. Association between coronary artery calcium score and plaque characteristics at the segment level.

<table>
<thead>
<tr>
<th></th>
<th>Coefficient</th>
<th>95% CI</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>TAV, mm³</td>
<td>0.087</td>
<td>0.024 to 0.149</td>
<td>.008</td>
</tr>
<tr>
<td>PAV, %</td>
<td>0.087</td>
<td>-0.028 to 0.087</td>
<td>.309</td>
</tr>
<tr>
<td>CaBi</td>
<td>0.117</td>
<td>0.048 to 0.186</td>
<td>.001</td>
</tr>
<tr>
<td>LCBi</td>
<td>0.082</td>
<td>-0.007 to 0.170</td>
<td>.070</td>
</tr>
<tr>
<td>maxLCBi</td>
<td>0.030</td>
<td>-0.014 to 0.074</td>
<td>.169</td>
</tr>
<tr>
<td>Coefficient of lesions detected by NIRS-IVUS</td>
<td>-0.084</td>
<td>-0.354 to 0.186</td>
<td>.537</td>
</tr>
<tr>
<td>Number of high-risk plaques</td>
<td>-0.233</td>
<td>-0.476 to 0.009</td>
<td>.059</td>
</tr>
</tbody>
</table>

CaBi, calcific burden index; LCBi, lipid core burden index; PAV, percent atheroma volume; TAV, total atheroma volume.
patients in our analysis does not allow us to draw safe conclusions; however, it appears that CACS has limited efficacy in predicting plaque extension and morphology in patients with established CAD. This has also been shown in a previous study comparing CACS and plaque characteristics in patients with stable and acute coronary syndrome. Therefore, in this setting, invasive or noninvasive imaging should be preferred for assessing plaque morphology, stratifying cardiovascular risk, and identifying vulnerable individuals who are likely to benefit from focal or systemic therapies targeting atherosclerosis. Considering the limited value of CACS to evaluate plaque morphology in our population, it can be hypothesized that CTA should be used instead of CACS as a screening tool in patients with a high probability of obstructive CAD as this enables comprehensive visualization of the coronary artery anatomy and detection of vulnerable lesions; this, however, needs to be proven by future large-scale clinical studies.

Limitations

Although this study is the largest report that examined the association between plaque morphology, derived by multimodality intravascular imaging and CACS, it has limitations that should be acknowledged. Firstly, the CACS was measured in contrast CTA using dedicated software and not in noncontrast CT that is conventionally used for this purpose. Noncontrast CT was not performed as per the study protocol to minimize the additional radiation associated with this test. However, today there is convincing evidence that contrast CTA provides an effective alternative for the computation of the CACS as multiple studies have shown a small bias and narrow limits of agreement between the CACS estimated by CTA and noncontrast CT. These evidences, the high reproducibility of the analysts, as well as the robust methodology implemented to compute the CACS that allowed use of the multiplanar images to ensure accurate calcific spot detection provide us confidence about the reported results. Secondly, this analysis included only patients who had obstructive CAD amenable to PCI as patients with advanced CAD, who usually have increased coronary calcification, and are referred for surgical revascularization, were excluded. It is unlikely, however, that this selection bias would have affected the main message of this analysis which was the high incidence of high-risk lesions in patients with 0 or very low CACS. Thirdly, the number of patients included was not sufficient to allow their classification in the CACS categories proposed by Rumberger et al to compare the plaque composition in different CACS groups. Fourthly, in our cohort, only 25 high-risk lesions were detected, a number that did allow a detailed assessment of the association between plaque phenotypes and CACS. A lesion-level comparison of the CACS values in high- and low-risk lesions may have increased our sample size and allowed us to partially overcome this limitation; however, the matching of the NIRS-IVUS and CT data at the lesion level was not possible with the CalciumScore software. Finally, predilatation was performed in 6 cases as the NIRS-IVUS catheter could not cross these lesions. This is likely to have only a minimum effect on the estimated lumen, vessel, and PAD as in all occasions a 2 mm balloon was used for predilatation and it is unlikely to have affected the TAV computation as balloon dilatation does not reduce the plaque volume but causes dissection, plaque redistribution, and vessel enlargement. Only 2 of the lesions that were predilated had a maxLCBI >400 and a PB <70% post predilatation and were not considered as high-risk lesions; this classification, however, may have been different if NIRS-IVUS was possible without balloon dilatation.

Conclusions

Coronary artery calcium score is associated with atheroma burden but it has a limited value in predicting the lipid burden and the presence of high-risk lesions in patients with obstructive CAD. Our findings indicate that this modality may have a limited value as a screening tool and to stratify cardiovascular risk in symptomatic patients with multiple risk factors who have a high probability of suffering from obstructive CAD. Considering, however, the small number of recruited patients and the selection bias, further research is needed in this direction and the conduction of large-scale analysis before drawing firm conclusions.
Declaration of competing interest

The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding sources

This study is jointly funded by the British Heart Foundation (grant number: PG/17/18/32883), University College London Biomedical Resource Centre (grant number: BRC492B), and Rosetrees Trust (grant number: A1773). Anantharaman Ramasamy, Retesh Bajaj, Andreas Baumbach, and Christos V. Bourantas are funded by Barts NIHR Biomedical Research Centre, London, United Kingdom.

Ethics statement and patient consent

The reported research has adhered to the relevant ethical guidelines; patient consent has been obtained from all the included patients.

Supplementary material

To access the supplementary material accompanying this article, visit the online version of the Journal of the Society for Cardiovascular Angiography & Interventions at 10.1016/j.jscad.2024.101308.

References